Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; none of the 47 sources its claims cite is checked for support yet.
Abstract
BACKGROUND: mRNA electroporation of dendritic cells (DCs) facilitates processing and presentation of multiple peptides derived from whole antigen, tailored to different HLA molecules. Clinical responses to electroporated moDC vaccines, however, have been suboptimal. Human Langerhans-type DCs (LCs) are the most potent conventional DC subtype for inducing CD8+ cytotoxic T lymphocytes (CTLs) in vitro. We recently demonstrated that Wilms' tumor 1 (WT1) mRNA-electroporated LCs are superior to moDCs as stimulators of tumor antigen-specific CD8+ CTLs, even though they are comparable stimulators of allogeneic T cell proliferative responses. A detailed comparative evaluation of the effects of mRNA electroporation on LCs versus moDCs, however, is needed. METHODS: Immature and partially-matured human moDCs and LCs electroporated with mRNA were compared for transfection efficiency, phenotypic changes, viability, retention of transgene expression after cryopreservation, and immunogenicity. Student t test was used for each pairwise comparison. One-way analysis of variance was used for multiple group comparisons. RESULTS: Transfection efficiency after electroporation with enhanced green fluorescent protein (eGFP) mRNA was higher for immature than for partially-matured moDCs. In contrast, transfection efficiency was higher for partially-matured than for immature LCs, with the additional benefit that electroporation itself increased maturation and activation of CD83+HLA-DRbright LCs but not moDCs. Electroporation did not impair final maturation and activation of either DC subtype, after which both mRNA-electroporated LCs and moDCs were functionally similar in stimulating allogeneic T cell proliferation, a standard assay of DC immunogenicity. CONCLUSIONS: These findings support mRNA electroporation of DCs, and in particular LCs, as an effective non-viral method to stimulate specific, potent CD8+ CTL responses. The differences between LCs and moDCs regarding this form of antigen-loading have important implications for DC-based immunotherapies.
Overview
CoChat Summary
TL;DR
mRNA electroporation of human dendritic cells is feasible, but transfection efficiency and maturation effects differ by DC subtype and maturation state: immature moDCs transfect better than partially matured moDCs, whereas partially matured LCs transfect better than immature LCs, and electroporation itself matures LCs more than moDCs. Both mRNA-electroporated moDCs and LCs remain viable, retain transgene expression after cryopreservation, and stimulate allogeneic T cell proliferation similarly.
Key findings
- Transfection efficiency after eGFP mRNA electroporation was higher for immature than partially-matured moDCs (peak at 24 hours: 77.9 ± 12.4% vs 59.4 ± 15.4%), but higher for partially-matured than immature LCs (peak at 48 hours: 67 ± 6.9% vs 55.2 ± 2.9%).
- Electroporation increased maturation/activation markers more strongly in LCs than moDCs: CD83+HLA-DRbright LCs rose from 29.62 ± 2.8% pre-electroporation to 96.92 ± 0.81% post-electroporation, whereas moDC CD83 rose from 10.68 ± 3.37% to 26.13 ± 3.34%; CD80 increased from 33.36 ± 1.65% to 77.03 ± 5.54% for LCs and from 4.9 ± 2.1% to 35.88 ± 7.11% for moDCs (fold increase 2.3 for LCs vs 7.3 for moDCs). Electroporation did not impair terminal cytokine-induced maturation of either subtype.
- Electroporation caused up to approximately 40% initial cell death, but after 24 hours viability was >85% for immature and partially-matured moDCs and LCs (e.g., 94.2 ± 3.0% for immature moDCs, 88.7 ± 6.3% for immature LCs, 87.1 ± 7.1% for partially-matured moDCs, 92.9 ± 3.8% for partially-matured LCs). Post-thaw viability and retention of eGFP expression after cryopreservation were similar between moDCs and LCs.
- mRNA-electroporated moDCs and LCs remained potent stimulators of allogeneic T cell proliferation in mixed leukocyte reactions, including after cryopreservation and thawing, with similar trends across mock-, eGFP mRNA-, and WT1 mRNA-electroporated DCs.
Methods
- Immature and partially-matured human moDCs were generated from PBMCs/CD14+ monocytes, and LCs were generated from G-CSF–elicited CD34+ hematopoietic progenitor cells; cells were electroporated with eGFP or WT1 mRNA and compared for transfection efficiency, phenotype, viability, cryopreservation retention, and allogeneic stimulatory capacity.
- Flow cytometry assessed eGFP and CD80/CD83/CD86/HLA-DR expression; viability was measured by trypan blue exclusion; allogeneic mixed leukocyte reactions used [3H]TdR uptake or a colorimetric proliferation assay.
- Student t test was used for pairwise comparisons, one-way ANOVA for multiple group comparisons, with P < .05 considered significant; independent experiment numbers included n = 6 for transfection, n = 3 for phenotype/MLR, and n = 4 for viability/cryopreservation assays.
Limitations
- Stated: peak transfection efficiency was lower for LCs than moDCs, possibly because moDCs derive from a more differentiated and committed starting population with greater purity, leaving contaminating non-LCs to compete for mRNA uptake; HLA-DR selection could increase LC transfection efficiency but may not be necessary if electroporated LCs are quantified by flow cytometry.
- Stated: electroporation conditions need revalidation across differences in electroporation machine, voltage, pulse number, cell concentration, or mRNA amount; cryopreservation can further decrease cell recovery, so excess electroporated DCs should be aliquoted. The paper also notes additional undiscovered reasons for LC potency and states it remains important to determine whether IL15-supplemented moDCs are an adequate substitute for LCs or whether the two subtypes should be combined.
- Evident from the text: the functional comparison here is allogeneic T cell proliferation, not antigen-specific CD8+ CTL killing or in vivo clinical responses; the study is in vitro, with small independent experiment numbers, and does not itself test mRNA-electroporated LC versus moDC vaccines in patients.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 6 mRNA-electroporated moDCs and LCs remain potent inducers of allogeneic T cell proliferation, including after cryopreservation and thawing. (A) MoDCs and LCs, as indicated on the x axes, were electroporated with WT1 mRNA (○), eGFP mRNA (△), or mock-electroporated with no mRNA (□). After electroporation, DCs were terminally matured for 24 hours and then cultured with allogeneic T cells for five days in allogeneic MLRs. DC:T ratios ranged from 1:10 to 1:1000. [3H]TdR uptake by proliferating allogeneic T cells over the final 8 hours of culture was measured as an index of DC immunogenicity (triplicate means ± SEM, n = 3 independent experiments). (B) To assess preservation of allo-stimulatory capacity in MLRs after cryopreservation and thawing, WT1 mRNA-electroporated moDCs (△) and LCs (○) were compared with non-cryopreserved mature moDCs (▤). Culture conditions were otherwise exactly the same as in (A). T cell proliferation was measured by a colorimetric assay (triplicate means ± SEM, n = 3 independent experiments). Dotted line represents T cells alone.](https://figures.cochat.ai/paper-figures/5ac63ccb092d47ac84a3053adcce9d17/langerhans-type-and-monocyte-derived-human-dendritic-cells-have-different-figure-6.jpg)
Verification
Claims the paper makes
0 Valid · 0 Not valid · 20 Not checked · 40 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For immature moDCs, best results were achieved with 700 V, 1 pulse, and 40 μg mRNA.”
§ Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy > Results > The transfection efficiency of mRNA electroporation varies with the maturation status of moDCs and LCs
plainstates a causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Immature and mature moDCs and LCs demonstrated >85% viability (Figure 4B; 94.2 ± 3.0% for immature moDCs and 88.7 ± 6.3% for immature LCs; 87.1 ± 7.1% for partially-matured moDCs and 92.9 ± 3.8% for partially-matured LCs).”
§ Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy > Results > Cell loss and viability of moDCs and LCs after electroporation and cryopreservation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“fold increase of CD80 expression was greater for moDCs (7.3-fold increase for moDC and 2.3-fold increase for LCs).”
§ Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy > Results > Immature LCs, in contrast to immature moDCs, display a more mature phenotype after mRNA electroporation
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Transfection efficiency after electroporation with enhanced green fluorescent protein (eGFP) mRNA was higher for immature than for partially-matured moDCs.”
- Also stated in: § The transfection efficiency of mRNA electroporation varies with the maturation status of moDCs and LCs · plain
“transfection efficiency was higher for immature than for partially-matured moDCs (peak value at 24 hours: 77.9 ± 12.4% for immature cells and 59.4 ± 15.4% for partially-matured cells).”
- Also stated in: § Discussion · plain
“immature moDCs showing more efficient transfection than mature moDCs.”
§ Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy > Abstract > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § The transfection efficiency of mRNA electroporation varies with the maturation status of moDCs and LCs · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For partially-matured LCs, best results were achieved with 700 V, 2 pulses, and 30 μg mRNA.”
§ Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy > Results > The transfection efficiency of mRNA electroporation varies with the maturation status of moDCs and LCs
plainstates a causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
24 more claims
Create a free account to see all 60 claims and to verify the 47 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 18
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy > Discussion
“Electroporation favorably induces the maturation of CD83+HLA-DRbright LCs, whereas electroporation has no direct effect on moDC maturation.”
§ Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy > Results > Immature LCs, in contrast to immature moDCs, display a more mature phenotype after mRNA electroporation
“Electroporation had a mild direct effect on moDC maturation based on expression of the prototypical DC maturation marker, CD83 (Figure 3A; 10.68 ± 3.37% pre-electroporation and 26.13 ± 3.34% post-electroporation)”
Citations
Cites
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Antigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926
Functional Specializations of Human Epidermal Langerhans Cells and CD14+ Dermal Dendritic Cells
Klechevsky, E., Morita, R., Liu, M., Cao, Y., Coquery, S., Thompson-Snipes, L., Briere, F., Chaussabel, D., Zurawski, G., Palucka, A. K., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.07.013 · Cited by 619
Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M. A., Lallas, C. D., Dahm, P., Niedzwiecki, D., Gilboa, E., & Vieweg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214364 · Cited by 562
Van Tendeloo, V. F. I., Ponsaerts, P., Lardon, F., Nijs, G., Lenjou, M., Van Broeckhoven, C., Van Bockstaele, D. R., & Berneman, Z. N. (2001) · Blood · doi:10.1182/blood.v98.1.49 · Cited by 468
Nair, S. K., Boczkowski, D., Morse, M., Cumming, R. I., Lyerly, H. K., & Gilboa, E. (1998) · Nature Biotechnology · doi:10.1038/nbt0498-364 · Cited by 398
Van Tendeloo, V. F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008051107 · Cited by 377 · cited 2×
“Electroporation of DCs with mRNA encoding specific tumor-associated antigens is an effective non-viral method to stimulate T cell responses in vitro and in vivo [4-11].”
BackgroundManipulating dendritic cell biology for the active immunotherapy of cancer
O'Neill, D. W., Adams, S., & Bhardwaj, N. (2004) · Blood · doi:10.1182/blood-2003-12-4392 · Cited by 339
Cancer immunotherapy with mRNA‐transfected dendritic cells
Gilboa, E., & Vieweg, J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00139.x · Cited by 316
Heiser, A., Dahm, P., R. Yancey, D., Maurice, M. A., Boczkowski, D., Nair, S. K., Gilboa, E., & Vieweg, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5508 · Cited by 187
Cited by
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy
Chung, D. J., Pronschinske, K. B., Shyer, J. A., Sharma, S., Leung, S., Curran, S. A., Lesokhin, A. M., Devlin, S. M., Giralt, S. A., & Young, J. W. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0055 · Cited by 212
Self-citationResearch progress on dendritic cell vaccines in cancer immunotherapy
Yu, J., Sun, H., Cao, W., Song, Y., & Jiang, Z. (2022) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00257-2 · Cited by 190
Messenger RNA (mRNA) nanoparticle tumour vaccination
Phua, K. K. L., Nair, S. K., & Leong, K. W. (2014) · Nanoscale · doi:10.1039/c4nr01346h · Cited by 70
Dendritic Cell Therapies for Hematologic Malignancies
Weinstock, M., Rosenblatt, J. M., & Avigan, D. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.004 · Cited by 63
Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens
Poveda, C., Biter, A. B., Bottazzi, M. E., & Strych, U. (2019) · Vaccines · doi:10.3390/vaccines7040131 · Cited by 54
“While some studies report equal transfection rates in different DCs 278 [57], there is evidence that the transfection efficiency for mRNA is lower for mDCs than it is for imDCs 279 [58].”
Background
Metadata
- Authors
- Chung, D. J., Romano, E., Pronschinske, K. B., Shyer, J. A., Mennecozzi, M., Angelo, E. T. S., & Young, J. W.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Chung, David J
- Venue
- Journal of Translational Medicine
- Published
- 2013-07-09
- Volume
- 11
- Issue
- 1
- Pages
- 166-166
- ISSN
- 1479-5876 (ISSN-L)
- PMC
- PMC3710267
- OpenAlex
- W2108060874
- Semantic Scholar
- 03af0227fe9e1959f11dc1c4b04b2fb64036b2cc
- Cited by
- 24
- References
- 26
- Citations by year
- 2026: 2 · 2025: 1 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 1 · 2017: 2 · 2016: 4 · 2014: 6 · 2013: 1
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- Journal of Translational Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- Memorial Sloan-Kettering Cancer Center
- Swim Across America
- European Commission (21027)
- Centre Hospitalier Universitaire Vaudois
- National Institutes of Health
- Weill Cornell Medical College
- Joint Research Centre
- National Cancer Institute (P01CA023766, R01CA118974, R01CA083070, R21CA119528, P30CA008748)
- Congressionally Directed Medical Research Programs
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Microbial Inactivation Methods
- Keywords
- dendritic cells, Langerhans cells, monocyte-derived dendritic cells, mRNA electroporation, dendritic cell maturation, dendritic cell activation, transfection efficiency, WT1 mRNA, CD8+ cytotoxic T lymphocytes, allogeneic T cell proliferation, dendritic cell immunotherapy, cryopreservation
- MeSH terms
- Cell Survival, Dendritic Cells, HLA Antigens, Humans, Immunotherapy, Islets of Langerhans, Monocytes, Phenotype, RNA, Messenger, T-Lymphocytes, Cytotoxic, Transfection, Granulocyte Colony-Stimulating Factor, Cytokines, Antigen Presentation, Electroporation, Transgenes, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy. https://app.cochat.ai/papers/10.1186/1479-5876-11-166
- The paper
- Chung, D. J., Romano, E., Pronschinske, K. B., Shyer, J. A., Mennecozzi, M., Angelo, E. T. S., & Young, J. W. (2013). Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-11-166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.